RAIN News and Press, Rain Therapeutics Inc. From 03/03/22

– Quarter-end cash position of $140.2 million provides runway to complete all ongoing and planned clinical trials of milademetan, including an ample cash cushion for the Phase 3 MANTRA trial in liposarcoma – – Enrollment in both Phase 3 liposarcoma trial (MA...

NEWARK, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced it will report financial results for the fourth quarter and full year ended December 31, 2021 a...

– Industry veterans from Loxo/Lilly, Gilead, Seagen and AltruBio join Rain to expand clinical and regulatory operations – – In addition, Rain announces Advisory role to the CEO and Leadership team of John Maraganore, Ph.D., a position held since March 2021 &...

NEWARK, Calif., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will prov...

B. Riley Securities virtual presentation scheduled for January 27 th at 3:30 pm ET Guggenheim Oncology virtual fireside chat scheduled for February 10 th at 4:00 pm ET NEWARK, Calif., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (Na...

NEWARK, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced a clinical supply agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the supply of the anti-...

Rain Therapeutics (NASDAQ:RAIN) is set to join the NASDAQ Biotechnology Index. The move is effective as of market open on December 20, 2021. Previously (Nov. 22): Dosing underway in Rain Therapeutics' mid-stage milademetan trial for advanced solid tumors For further details see: Rain Th...

NEWARK, Calif., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced it will be added to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective as of market open o...

NEWARK, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will participa...

Rain Therapeutics (NASDAQ:RAIN) announces that the first patient has been dosed in the Phase 2 basket trial evaluating milademetan, an oral mouse double minute 2 (MDM2) inhibitor, for the treatment of MDM2-amplified advanced solid tumors. Approx. 65 patients are anticipated to be enrolle...